Author name: Claritas Rx

Buy and Bill

Exploring the Buy-and-Bill Model: Strategies and Trends in Pharmaceutical Distribution

Navigating the complex world of pharmaceutical distribution can be daunting for market access teams and pharmaceutical professionals. At the heart of this complexity lies the buy-and-bill model, a predominant method for distributing provider-administered drugs. This blog post aims to clarify how the buy-and-bill model works, explore its benefits and challenges, and provide insights into emerging […]

Exploring the Buy-and-Bill Model: Strategies and Trends in Pharmaceutical Distribution Read More »

Biopharma Fed Rate Cut

The Federal Reserve’s Impact on Biopharma: Opportunities and Challenges Amidst Interest Rate Cuts

The Federal Reserve’s recent decision to cut interest rates has sent ripples through various industries, but what does it mean for biopharma? Last week, the Fed announced a rate cut by half a percentage point, marking the first reduction since March 2020. This move has been met with a mixture of optimism and caution within

The Federal Reserve’s Impact on Biopharma: Opportunities and Challenges Amidst Interest Rate Cuts Read More »

Vironexis’ Bold Entrance Into Cancer Gene Therapy

Emerging from stealth mode with a bang, Vironexis Biotherapeutics has announced a successful $26 million seed funding round. This is not just another startup story; it’s a significant development in the realm of cancer gene therapy. For pharmaceutical professionals and biopharma executives, understanding Vironexis’ vision and innovations could provide crucial insights into the future of

Vironexis’ Bold Entrance Into Cancer Gene Therapy Read More »

AI Predictive Analytics for Patient Drop-Off

Using AI to Predict Patient Drop-Off and Enhance Treatment Adherence

In the rapidly evolving landscape of healthcare, patient adherence to treatment plans remains a critical challenge. For patient access teams, predicting which patients are at risk of dropping off their treatment regimens can be the difference between successful outcomes and unmet medical needs. Enter AI predictive analytics—a game changer for enhancing treatment adherence and transforming

Using AI to Predict Patient Drop-Off and Enhance Treatment Adherence Read More »

Pharmaceutical Launch Benchmarking

Benchmarking Strategies for Pharmaceutical Product Launches

Launching a pharmaceutical product can resemble navigating a labyrinth. For market access teams, the stakes are high. Implementing a successful launch strategy requires not just innovation but also strategic precision. This is where benchmarking steps in. By comparing your product’s potential performance against industry standards and competitors, you gain invaluable insights. This blog will walk

Benchmarking Strategies for Pharmaceutical Product Launches Read More »

Medication Adherence Technology

How Emerging Technology is Transforming Medication Adherence

The Challenge of Medication Non-Adherence in Specialty Pharmacy Medication adherence refers to whether patients take their medications as prescribed, including the correct dose, at the correct times, and for the prescribed duration. It is a crucial aspect of managing chronic conditions and maintaining overall health. Despite its importance, medication non-adherence is a significant issue. It

How Emerging Technology is Transforming Medication Adherence Read More »

GSK and Flagship Pioneering Partnership

Power of Biopharma Partnerships: GSK and Flagship Pioneering

Introduction In the fast-paced world of biopharma, partnerships can drive remarkable advancements. GlaxoSmithKline (GSK), a global healthcare leader, is taking a bold step by teaming up with Flagship Pioneering, a trailblazer in venture creation and life sciences innovation. This collaboration aims to develop up to 10 new vaccines and pharmaceuticals, initially focusing on the respiratory

Power of Biopharma Partnerships: GSK and Flagship Pioneering Read More »

Donanemab, Alzheimer's drug

Eli Lilly’s Urgent Push for Alzheimer’s Treatment Revolution

Introduction In the tough terrain of finding an Alzheimer’s cure, Eli Lilly is setting the pace with their latest innovation – the FDA-approved drug, Donanemab, commercially known as Kisunla. This blog delves into Lilly’s strategic maneuvers to expedite sales and cultivate urgent demand within the pharmaceutical sector. The vast population of patients combined with a

Eli Lilly’s Urgent Push for Alzheimer’s Treatment Revolution Read More »